Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression
- 1 August 2004
- journal article
- clinical trial
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 19 (8) , 828-834
Abstract
BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N=429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P=.007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.Keywords
This publication has 16 references indexed in Scilit:
- Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking CessationAnnals of Internal Medicine, 2001
- Smoking cessation and the course of major depression: a follow-up studyThe Lancet, 2001
- The Effects of Transdermal Nicotine Therapy for Smoking Cessation on Depressive Symptoms in Patients with Major DepressionNeuropsychopharmacology, 2001
- Smoking and Mental IllnessJAMA, 2000
- Development of Major Depression After Treatment for Smoking CessationAmerican Journal of Psychiatry, 2000
- History and symptoms of depression among smokers during a self-initiated quit attemptNicotine & Tobacco Research, 1999
- Effect of history of alcoholism or major depression on smoking cessationAmerican Journal of Psychiatry, 1993
- Heavy Smokers, Smoking Cessation, and ClonidineJAMA, 1988
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatmentAddictive Behaviors, 1978